{"disease":{"id":"x-linked-retinitis-pigmentosa","name":"x linked retinitis pigmentosa"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03584165","title":"Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":330,"lead_sponsor_name":"NightstaRx Ltd, a Biogen Company","has_results":false},{"nct_id":"NCT04926129","title":"Natural History of the Progression of X-Linked Retinitis Pigmentosa","phase":"","overall_status":"COMPLETED","enrollment_count":201,"lead_sponsor_name":"NightstaRx Ltd, a Biogen Company","has_results":false},{"nct_id":"NCT06982417","title":"InsightRP2 Registry","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"University of Göttingen","has_results":false},{"nct_id":"NCT04671433","title":"Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT04794101","title":"Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":97,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT04850118","title":"A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":85,"lead_sponsor_name":"Beacon Therapeutics","has_results":false},{"nct_id":"NCT03116113","title":"A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Biogen","has_results":true},{"nct_id":"NCT03252847","title":"Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"MeiraGTx UK II Ltd","has_results":true},{"nct_id":"NCT04312672","title":"Long-term Follow-up Gene Therapy Study for RPGR- XLRP","phase":"","overall_status":"COMPLETED","enrollment_count":42,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT06492850","title":"Gene Therapy for RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Frontera Therapeutics","has_results":false},{"nct_id":"NCT06646289","title":"A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":24,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT05874310","title":"Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Frontera Therapeutics","has_results":false},{"nct_id":"NCT04868916","title":"An Observational Study of Japanese Participants With X-linked Retinitis Pigmentosa","phase":"","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Janssen Pharmaceutical K.K.","has_results":false},{"nct_id":"NCT03314207","title":"Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)","phase":"","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Beacon Therapeutics","has_results":false},{"nct_id":"NCT07174726","title":"A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Beacon Therapeutics","has_results":false}],"total":15},"guidelines":[],"source":"Drug Landscape verified database"}